logo
HIMS Announcement: Kessler Topaz Meltzer & Check, LLP Encourages Hims & Hers Health, Inc. (HIMS) Investors to Contact the Firm About Securities Fraud Class Action Lawsuit

HIMS Announcement: Kessler Topaz Meltzer & Check, LLP Encourages Hims & Hers Health, Inc. (HIMS) Investors to Contact the Firm About Securities Fraud Class Action Lawsuit

RADNOR, PA - July 19, 2025 ( NEWMEDIAWIRE ) - The law firm of Kessler Topaz Meltzer & Check, LLP ( www.ktmc.com ) informs investors that securities class action lawsuits have been filed in the United States District Court for the Northern District of California against Hims & Hers Health, Inc. ('Hims & Hers') ( NYSE: HIMS ) on behalf of those who purchased or otherwise acquired Hims & Hers securities between April 29, 2025, and June 23, 2025, inclusive (the 'Class Period'). The lead plaintiff deadline is August 25, 2025.
CONTACT KESSLER TOPAZ MELTZER & CHECK, LLP:
If you suffered Hims & Hers losses, you may CLICK HERE or copy and paste the following link into your browser: https://www.ktmc.com/new-cases/hims-hers-health-inc?utm_source=NewMediaWire&utm_medium=PR
You can also contact attorney Jonathan Naji, Esq. by calling (484) 270-1453 or by email at [email protected].
DEFENDANTS' ALLEGED MISCONDUCT:
The complaints allege that, throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the company's business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) Hims & Hers was engaged in the 'deceptive promotion and selling of illegitimate, knockoff versions of Wegovy that put patient safety at risk;' (2) as a result, there was a substantial risk that Hims & Hers' collaboration with Novo Nordisk would be terminated; and (3) that, as a result of the foregoing, Defendants' positive statements about the company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
Please CLICK HERE to view our video or copy and paste this link into your browser: https://youtu.be/xuStgUOFgE8
THE LEAD PLAINTIFF PROCESS:
Hims & Hers investors may, no later than August 25, 2025, seek to be appointed as a lead plaintiff representative of the class through Kessler Topaz Meltzer & Check, LLP or other counsel, or may choose to do nothing and remain an absent class member. A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation. The lead plaintiff is usually the investor or small group of investors who have the largest financial interest and who are also adequate and typical of the proposed class of investors. The lead plaintiff selects counsel to represent the lead plaintiff and the class and these attorneys, if approved by the court, are lead or class counsel. Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff.
Kessler Topaz Meltzer & Check, LLP encourages Hims & Hers investors who have suffered significant losses to contact the firm directly to acquire more information.
CLICK HERE TO SIGN UP FOR THE CASE OR GO TO: https://www.ktmc.com/new-cases/hims-hers-health-inc?utm_source=NewMediaWire&utm_medium=PR
ABOUT KESSLER TOPAZ MELTZER & CHECK, LLP:
Kessler Topaz Meltzer & Check, LLP prosecutes class actions in state and federal courts throughout the country and around the world. The firm has developed a global reputation for excellence and has recovered billions of dollars for victims of fraud and other corporate misconduct. All of our work is driven by a common goal: to protect investors, consumers, employees and others from fraud, abuse, misconduct and negligence by businesses and fiduciaries. The complaint in this action was not filed by Kessler Topaz Meltzer & Check, LLP. For more information about Kessler Topaz Meltzer & Check, LLP please visit www.ktmc.com.
CONTACT:
Kessler Topaz Meltzer & Check, LLP
Jonathan Naji, Esq.
(484) 270-1453
280 King of Prussia Road
Radnor, PA 19087
[email protected]
May be considered attorney advertising in certain jurisdictions. Past results do not guarantee future outcomes.
View the original release on www.newmediawire.com
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Stock Movers: Novo Nordisk, Palo Alto, Union Pacific
Stock Movers: Novo Nordisk, Palo Alto, Union Pacific

Bloomberg

time6 hours ago

  • Bloomberg

Stock Movers: Novo Nordisk, Palo Alto, Union Pacific

On this edition of Stock Movers: - Novo Nordisk (NVO) shares close down 23%, erasing more than $73 billion in market value, after the maker of Wegovy and Ozempic cut its sales and profit forecasts, citing slumping sales of weight-loss drugs. The Danish drugmaker also named a company insider as its new CEO, which one investor said may disappoint those hoping for a radical shake-up under an external hire. It was the stock's steepest one-day drop on record and took the shares to the lowest level since March 2022. - Palo Alto Networks (PANW) shares fell after the Wall Street journal reported that the company is in talks to buy CyberArk Software Ltd. (CYBR) in a deal that could value the Israeli cybersecurity firm at more than $20 billion. Palo Alto Networks may finalize a deal as soon as this week, the Journal reported Tuesday, citing people familiar with the matter whom it didn't identify. CyberArk declined to comment. Palo Alto Networks didn't respond to a request for comment. - Union Pacific (UNP) shares are down today. The company agreed to acquire Norfolk Southern Corp. (NSC) in a $72 billion cash-and-stock transaction, forming the only US transcontinental railroad in what stands to be the industry's largest deal ever. The tie-up will marry Union Pacific's network across the western US with Norfolk's East Coast routes, reshaping a domestic rail market that's now comprised of just a half-dozen companies. Observers predict other major deals could follow, as competitive pressure rises on rivals including CSX Corp. and Berkshire Hathaway Inc.'s BNSF. 'We think the political environment is accommodating,' Union Pacific Chief Executive Officer Jim Vena said Tuesday in an interview. The companies have already spoken with regulators, members of the Trump administration and congressional lawmakers. 'We wouldn't have taken this path if we had not engaged and understood what they needed to see us deliver and whether we could.'

Novo Nordisk Shares Plunge, Drag Down Weight-Loss-Drug ETFs
Novo Nordisk Shares Plunge, Drag Down Weight-Loss-Drug ETFs

Yahoo

time6 hours ago

  • Yahoo

Novo Nordisk Shares Plunge, Drag Down Weight-Loss-Drug ETFs

Shares of Danish pharmaceutical giant Novo Nordisk A/S (NVO) tumbled 22% Tuesday after the company slashed its 2025 outlook and announced a CEO change, sending shockwaves through a range of ETFs tied to weight-loss drugs. Novo, best known for pioneering GLP-1 drugs like Ozempic and Wegovy, now expects sales to grow 8% to 14% this year, down from a prior range of 13% to 21%. Operating profit guidance was similarly lowered to 10% to 16% from a previous estimate of 16% to 24%. Invest in Gold American Hartford Gold: #1 Precious Metals Dealer in the Nation Priority Gold: Up to $15k in Free Silver + Zero Account Fees on Qualifying Purchase Thor Metals Group: Best Overall Gold IRA The stock is now down 66% from its mid-2024 highs, erasing hundreds of billions in market cap and pressuring several ETFs with heavy exposure to the once high-flying name. Novo is the top holding in the Roundhill GLP-1 & Weight Loss ETF (OZEM), with a 17% weighting. It also makes up 11% of the Amplify Weight Loss Drug & Treatment ETF (THNR) and 8% of the VanEck Pharmaceutical ETF (PPH). A leveraged ETF tied directly to the stock, the Defiance Daily Target 2X Long NVO ETF (NVOX), fell more than 40% on the day. Novo Decline Impacts OZEM, Weight-Loss ETFs Thematic ETFs tied to the GLP-1 boom have been hit hard by Novo's collapse. OZEM fell more than 5% on Tuesday, while THNR dropped 3%. Traditional pharma ETFs like PPH also declined, though to a lesser extent. The leveraged NVOX ETF posted one of the steepest declines in the entire ETF universe. For a full list of ETFs that hold Novo Nordisk, check out Novo Nordisk stock page. Compounding Problems In a press release, Novo Nordisk attributed the lowered guidance in part to persistent use of compounded GLP-1 drugs—custom-made knockoffs that some clinics continue to sell even after the FDA ended its temporary allowance for such practices in May. 'Despite the expiry of the FDA grace period for mass compounding on 22 May 2025, unsafe and unlawful mass compounding has continued,' the company said. 'Multiple entities continue to market and sell compounded GLP-1s under the false guise of 'personalisation' ... exposing patients to the significant risks posed by knockoff 'semaglutide' drugs made with illicit or inauthentic foreign active pharmaceutical ingredients.' Novo has launched litigation and is calling on regulators to crack down more aggressively, but the damage is already being felt. The easy availability of cheaper compounded alternatives is undercutting demand for Wegovy and Ozempic, especially in the U.S., where insurers remain reluctant to cover the pricey branded versions. NVO Falling Behind LLY At the same time, Novo is also facing growing competitive pressure from Eli Lilly and Co. (LLY), which has seen blockbuster success with its GLP-1 drug Zepbound. Some studies suggest Zepbound may be more effective than Wegovy, giving Lilly the edge both clinically and commercially. Adding to the uncertainty, Novo also announced that Maziar Mike Doustdar will succeed Lars Fruergaard Jørgensen as CEO. Doustdar previously led international operations and will now be tasked with navigating one of the most turbulent periods in the company's recent | © Copyright 2025 All rights reserved

Cheesecake Factory: Q2 Earnings Snapshot
Cheesecake Factory: Q2 Earnings Snapshot

San Francisco Chronicle​

time6 hours ago

  • San Francisco Chronicle​

Cheesecake Factory: Q2 Earnings Snapshot

CALABASAS HILLS, Calif. (AP) — CALABASAS HILLS, Calif. (AP) — The Cheesecake Factory Inc. (CAKE) on Tuesday reported second-quarter earnings of $54.8 million. On a per-share basis, the Calabasas Hills, California-based company said it had profit of $1.14. Earnings, adjusted for one-time gains and costs, were $1.16 per share. The results beat Wall Street expectations. The average estimate of 10 analysts surveyed by Zacks Investment Research was for earnings of $1.06 per share. The restaurant chain posted revenue of $955.8 million in the period, also surpassing Street forecasts. Nine analysts surveyed by Zacks expected $946.8 million. _____

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store